John Zuris

USPTO Granted Patents = 14 (Patent Applications = 11)

EPO Patents = 3 (Patent Applications = 1)

Average Co-Inventor Count = 3.7

ph-index = 5

Forward Citations = 372(Granted Patents)

Location History:

Cambridge, MA (US) (2016 - 2024)
Boston, MA (US) (2024)

Company Filing History:

Massachusetts Eye and Ear Infirmary

patents

4 out of 50

Editas Medicine, Inc.

patents

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12325854 - Crispr-CPF1-related methods, compositions and components for cancer immunotherapy (2025-06-10),

2. 12102691 - Methods for efficient delivery of therapeutic molecules in vitro and in vivo (2024-10-01),

3. 12049651 - Cas9 fusion molecules, gene editing systems, and methods of use thereof (2024-07-30),

4. 12043653 - Efficient delivery of therapeutic molecules to cells of the inner ear (2024-07-23),

5. 12031132 - Systems and methods for the treatment of hemoglobinopathies (2024-07-09),

6. 11370823 - Efficient delivery of therapeutic molecules to cells of the inner ear (2022-06-28),

7. 11236313 - Cas9 fusion molecules, gene editing systems, and methods of use thereof (2022-02-01),

8. 11071790 - Method for efficient delivery of therapeutic molecules in vitro and in vivo (2021-07-27),

9. 10912833 - Delivery of negatively charged proteins using cationic lipids (2021-02-09),

10. 10682410 - Delivery system for functional nucleases (2020-06-16),

11. 10258697 - Efficient delivery of therapeutic molecules in vitro and in vivo (2019-04-16),

12. 9999671 - Delivery of negatively charged proteins using cationic lipids (2018-06-19),

13. 9737604 - Use of cationic lipids to deliver CAS9 (2017-08-22),

14. 9526784 - Delivery system for functional nucleases (2016-12-27),

Title: John Zuris: Innovator in Cancer Immunotherapy and Gene Editing

Introduction

John Zuris is a prominent inventor based in Cambridge, MA, known for his significant contributions to the fields of cancer immunotherapy and gene editing. With a total of 14 patents to his name, Zuris has made remarkable strides in developing innovative methods and compositions that address critical health challenges.

Latest Patents

Among his latest patents, Zuris has focused on CRISPR/Cpf1-related methods, compositions, and components for cancer immunotherapy. These innovations aim to enhance the treatment of cancer through advanced gene editing techniques. Additionally, he has developed methods for the efficient delivery of therapeutic molecules both in vitro and in vivo. His compositions are designed for direct protein delivery into various cell types in the mammalian inner ear, targeting genetic mutations associated with deafness and related disorders. These groundbreaking methods include the intracellular delivery of genome editing proteins, which are essential for correcting genetic mutations and potentially restoring hearing.

Career Highlights

Throughout his career, John Zuris has worked with esteemed institutions such as Harvard College and Massachusetts Eye and Ear Infirmary. His work has not only advanced scientific understanding but has also paved the way for new therapeutic approaches in medicine.

Collaborations

Zuris has collaborated with notable individuals in the field, including David R. Liu and David B. Thompson. These partnerships have contributed to the development of innovative solutions in gene editing and therapeutic delivery.

Conclusion

John Zuris stands out as a leading inventor whose work in cancer immunotherapy and gene editing has the potential to transform medical treatments. His dedication to innovation continues to inspire advancements in the scientific community.

This text is generated by artificial intelligence and may not be accurate.